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INTRODUCTION
Infections are one of the leading causes of morbidity
and mortality among renal transplant recipients. In these
patients, Aspergillus is a common cause of systemic
fungal disease, with an incidence ranging from 0.4%
to 2.4%, and a high mortality of 56–100% [1,2]. We
describe a case of cutaneous aspergillosis that present-
ed with subcutaneous nodules coexisting with end-
ophthalmitis and pulmonary tuberculosis in a renal
transplant recipient.
CASE REPORT
A 70-year-old Chinese man with long-standing
hypertension and end-stage renal failure due to un-
known cause was initiated on regular hemodialysis
twice weekly since 2002. He underwent cadaveric renal
transplantation in mainland China in December 2006.
After the transplantation, he received triple therapy
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including prednisolone, tacrolimus and mycophenolate
mofetil (MMF) as the maintenance immunosuppressive
regimen. There was no history of induction therapy.
He was discharged from hospital with a serum
creatinine level of 197 +mol/L.
He developed fever and pancytopenia when he came
back to our center for follow-up in January 2007. Blood
test revealed the following: hemoglobin 6.8 g/dL;
white blood cell (WBC) count 2.8 × 109/L; platelet
count 111 × 109/L; serum creatinine concentration 126
+mol/L; cytomegalovirus (CMV) pp65 antigen 1
positive cell per 2 × 105 cells. He was treated with
valganciclovir 450 mg daily for 3 weeks in view of the
possibility of CMV disease. The tacrolimus trough level
was 12.2 +g/L. The dosage of tacrolimus was reduced
and MMF was switched to azathioprine in view of the
possibility of bone marrow suppression due to MMF.
Bone marrow aspiration was planned but not done
because the fever subsided with normalization of
complete blood count after treatment. The CMV pp65
antigen test was repeated and the result was negative.
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In May 2007 (6 months after transplant), he
complained of a painful and red left eye. There was
also blurring of vision. He was diagnosed to have left
endophthalmitis by our ophthalmologist, and was
admitted to hospital for further management. There was
no fever on presentation. Laboratory investigations
revealed the following: hemoglobin 10.4 g/dL; WBC
count 4.5 × 109/L; platelet count 262 × 109/L; sodium
concentration 136 mmol/L; potassium concentration
5.1 mmol/L; serum creatinine concentration 115 +mol/
L; C-reactive protein 75.6 mg/L; CMV pp65 antigen was
negative. Tacrolimus level was within the therapeutic
range. Left eye vitreous tapping was done. Bacterial
culture, fungal culture and polymerase chain reaction
assay for CMV of vitreous fluid were all negative.
At the same time, the patient was noted to have two
subcutaneous skin nodules measuring 1.5 cm in
diameter, one on the right flank and the other on the
right thigh. Both nodules were present for 2 weeks and
there was no history of skin injury. Excisional biopsies
of the skin nodules were done. The histology of both
skin nodules showed fungal infection favoring
aspergillosis (Figure 1). Tissue fungal culture grew
Aspergillus fumigatus. Blood for galactomannan was
negative and blood for (1,3)-`-D-glucan titer was > 500
pg/mL. He was treated for disseminated aspergillosis.
Voriconazole 200 mg twice daily was started. The
dosage of tacrolimus was further reduced in view of
the presence of fungal infection and drug interaction
with voriconazole. The tacrolimus level was closely
monitored. Computed tomography (CT) scan of the
brain was unremarkable and echocardiography revealed
no features of infective endocarditis. Although the
redness and pain of the left eye resolved, visual acuity
remained light perception only.
One week later, he complained of persistent fever
despite a course of cefoperazone/sulbactam (sul-
perazone). There was no cough, sputum or shortness
of breath. There was also no dysuria or diarrhea. His
ocular condition remained static. No more skin nodules
were noted. Laboratory investigations revealed the
following: hemoglobin 10.9 g/dL; WBC count 2.3 ×
109/L; neutrophil count 1.2 × 109/L; lymphocyte count
0.9 × 109/L; platelet count 262 × 109/L; C-reactive
protein 56.9 mg/L. Liver and renal function tests were
normal, CMV pp65 antigen was negative, and blood
and urine culture were negative. Chest X-ray revealed
mild pulmonary infiltrate over hilar regions. Abdominal
ultrasound showed no significant abnormality. CT scan
of the thorax showed multifocal and bilateral small
pulmonary nodules with an oval soft tissue nodule at
the right mediastinum adjacent to the ascending aorta
that looked likely to be adenopathy (Figure 2). Fine
needle aspiration of the lung nodules revealed reactive
changes with necrosis only. The bacterial culture, fungal
culture and acid-fast bacilli (AFB) culture of the aspirate
were all negative.
Figure 2. Computed
tomography scan of the
thorax shows multifocal
and bilateral small
pulmonary nodules.
Figure 1. High power view of the fungal organisms in biopsy of
the skin nodule: regularly straight septated hyphae, branching at
acute angle or occasional right angle, ovoid spore-like structures
mingle with the hyphae (hematoxylin & eosin).
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AFB staining of sputum was subsequently positive
(4+) and he was diagnosed to have co-infection of
pulmonary tuberculosis with aspergillosis. Anti-
tuberculosis therapy including isoniazid, ethambutol,
pyrazinamide, morxifloxacin and vitamin B6 was
started. Sputum AFB culture confirmed the presence
of Mycobacterium tuberculosis. His fever responded to
the antituberculosis therapy and he was discharged
with voriconazole and antituberculosis medication. His
renal function remained stable on discharge. At the
6-month follow-up, his chest X-ray was clear and there
was no evidence of aspergillosis recurrence.
DISCUSSION
Cutaneous involvement is a rare manifestation of
aspergillosis. Cutaneous infection is reported in only
5% of documented Aspergillus infections, and can be
primary or secondary [3]. Primary cutaneous
aspergillosis occurs as a result of direct inoculation of
the fungus into breaks in the skin and commonly
involves sites of skin injury [4,5]. On the other hand,
the secondary form is rare. It develops as a result of
hematogenous or contagious spread from an underlying
infected organ [4]. Most of the infections are caused
by Aspergillus fumigatus [5], as in our patient.
Endophthalmitis is also an unusual infection in renal
transplant recipients [6]. In our patient, the exact
causative organism of the endophthalmitis could not
be confirmed because of the negative culture results
and the absence of histology. However, the coexisting
cutaneous aspergillosis with resolution of ocular
inflammation after the administration of antifungal
agent suggests that Aspergillus fumigatus was the
causative agent of endophthalmitis in our patient. The
incidence of Aspergillus endophthalmitis is not known,
but a recent study identified 89 cases over the last 50
years, with 23% occurring in solid organ transplants
[7]. The prognosis of Aspergillus endophthalmitis in
renal transplant patients is poor as the organisms might
already have disseminated to other sites, and recovery
of vision is unlikely due to extensive retinal necrosis
and choroidal damage [8].
Our patient received potent immunosuppressive
agents including corticosteroids, tacrolimus and MMF,
which rendered him vulnerable to opportunistic
infections. Recent studies show that use of MMF is
associated with a higher incidence of infections including
CMV and Aspergillus [9]. CMV infection itself has been
suggested to predispose to aspergillosis in transplant
recipients [10]. Furthermore, corticosteroids are known
to inhibit macrophage and neutrophil function, which
are the most important cells in the host defense against
Aspergillus [11]. Amphotericin B, itraconazole and
voriconazole are the major therapeutic options for
disseminated aspergillosis [4,12]. While amphotericin
B has been the standard therapy for systemic asper-
gillosis, it has recently been shown that voriconazole
leads to better responses, improved survival and fewer
side effects compared with amphotericin B [12]. Both
amphotericin B and itraconazole have poor intraocular
penetration [13,14]. On the other hand, voriconazole has
been shown to have good concentration in aqueous
humor [15] and has fungicidal action against Aspergillus
fumigatus. Our patient was put on voriconazole because
we suspected that he had Aspergillus endophthalmitis to
start with, and his ocular inflammation responded well
to voriconazole therapy. The duration of voriconazole
therapy depends on whether the patient is in an
immunocompromised state. As long as our patient is
on immunosuppressive agents, voriconazole will be
continued.
Pulmonary involvement is a common presentation
in disseminated aspergillosis. However, as in our
patient, not all pulmonary nodules in a patient with
disseminated aspergillosis are due to Aspergillus
fumigatus. Although one-man one-disease is the general
rule, immunocompromised patients may have several
co-infections. We should try hard to rule out other
coexisting pulmonary infections, such as bacterial
pneumonia, CMV pneumonitis or mycobacterial
infection. Mycobacterial infection is a particularly
impor tant  considera t ion  in  endemic  areas .
Microbiologic or histologic diagnosis of pulmonary
lesions should be obtained in all transplant recipients.
When all the findings are negative, bronchoscopy might
be helpful to make correct diagnosis for prompt and
appropriate therapy. In our patient, the occurrence of
persistent fever and abnormal pulmonary infiltrates
despite voriconazole suggested that other opportunis-
tic infections were present. Pulmonary tuberculosis
was finally diagnosed by sputum results. The symptoms
and abnormal radiologic features resolved after
antituberculosis therapy. The duration of the
antituberculosis therapy was at least 1 year.
As infections are one of the leading causes of
morbidity and mortality among immunocompromised
patients, early diagnosis and prompt treatment are
important. Immunocompromised patients might have
atypical presentation of common infections, such as
cutaneous or ocular aspergillosis. The possibility of co-
infection should always be borne in mind, especially
when the patient’s clinical condition fails to respond
favorably to initial treatment.
REFERENCES
1. Cornet M, Fleury L, Maslo C, Bernard JF, Brücker G; Invasive
Aspergillosis Surveillance Network of the Assistance Publique-
Hôpitaux de Paris. Epidemiology of invasive aspergillosis in
Hong Kong J Nephrol • October 2008 • Vol 10 • No 2 77
Aspergillosis in a renal transplant patient
France: a six-year multicenter survey in the Greater Paris area.
J Hosp Infect 2002;51:288–96.
2. Lin SJ, Schranz J, Teutsch SM. Aspergilllosis case-fatality rate:
systemic review of the literature. CID 2001;32:358–66.
3. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard
JR, Dupont B, et al. Invasive aspergillosis. Disease spectrum,
treatment practices, and outcomes. I3 Aspergillus Study Group.
Medicine (Baltimore) 2000;79:250–60.
4. Van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis.
J Clin Microbiol 1998;36:3115–21.
5. Ricci RM, Evans JS, Meffert JJ, Kaufman L, Sadkowski LC.
Primary cutaneous Aspergillus ustus infection: second reported
case. J Am Acad Dermatol 1998;38:797–8.
6. Schelenz S, Goldsmith DJA. Aspergillus endophthalmitis: an
unusual complication of disseminated infection in renal transplant
patients. J Infect 2003;47:336–43.
7. Riddell Iv J, McNeil SA, Johnson TM, Bradley SF, Kazanjian
PH, Kauffman CA. Endogenous Aspergillus endophthalmitis:
report of 3 cases and review of the literature. Medicine (Baltimore)
2002;81:311–320.
8. Rao NA, Hidayat AA. Endogenous mycotic endophthalmitis:
variations in clinical and histopathologic changes in candidiasis
compared with aspergillosis. Am J Ophthalmol 2001;132:244–51.
9. US Renal Transplant Mycophenolate Mofetil Study Group.
Mycophenolate mofetil in cadaveric renal transplantation. Am J
Kidney Dis 1999;34:296–303.
10. Husni RN, Gordon SM, Longworth DL, Arroliga A, Stillwell PC,
Avery RK, et al. Cytomegalovirus infection is a risk factor for
invasive aspergillosis in lung transplant recipients. Clin Infect Dis
1998;26:753–5.
11. Schaffner A, Schaffner T. Glucocorticoid-induced impairment of
macrophage antimicrobial activity: mechanisms and dependence
on the state of activation. Rev Infect Dis 1987;9:S620–9.
12. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE,
Oestmann JW, et al; Invasive Fungal Infections Group of the
European Organisation for Research and Treatment of Cancer and
the Global Aspergillus Study Group. Voriconazole versus
amphotericin B for primary therapy of invasive aspergillosis. N
Engl J Med 2002;347:408–15.
13. Fisher JF, Taylor AT, Clark J, Rao R, Espinel-Ingroff A.
Penetration of amphotericin B into the human eye. J Infect Dis
1983;147:164.
14. Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new
azole compounds into the eye and efficacy in experimental Candida
endophthalmitis. Antimicrob Agents Chemother 1987;31:6–10.
15. Zhou L, Glickman RD, Chen N, Sponsel WE, Graybill JR, Lam
KW. Determination of voriconazole in aqueous humor by liquid
chromatography-electrospray ionization-mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci 2002;776:213–
20.
